Product Images Atorvastatin Calcium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Atorvastatin Calcium NDC 68071-5246 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

PDP - 68071 5246 9

PDP - 68071 5246 9

This is a label for Atorvastatin Calcium 20mg tablets, manufactured by NuCare Pharmaceuticals Inc. The lot number for this batch is 000000, and the tablets are sold in a bottle of 90. Patients should refer to the manufacturer's label for a full list of ingredients. The tablets should be stored at a controlled temperature of 68-77°F, and kept out of reach of children. Contact the FDA at 1-800-FDA-1088 to report any side effects.*

Chemical Structure - atorvastatin calcium tablets 1

Chemical Structure - atorvastatin calcium tablets 1

Figure 1 - atorvastatin calcium tablets 2

Figure 1 - atorvastatin calcium tablets 2

The text provides a graph of the cumulative incidence for a particular event over a 35-year period. There are percentages listed at 404%, 30%, and 15% over the years. An HR value of 0.64 is also given with confidence interval (0.50-0.83) and a p-value of 0.0005. The meaning and context of this information cannot be determined without additional information.*

Figure 2 - atorvastatin calcium tablets 3

Figure 2 - atorvastatin calcium tablets 3

This text represents some statistics related to a medical study. It includes the cumulative hazard percentage over time, the hazard ratio, and the time to the first primary endpoint through four years of follow-up. There is insufficient information to provide further details or context.*

Figure 3 - atorvastatin calcium tablets 4

Figure 3 - atorvastatin calcium tablets 4

The text shows a table or graph of subjects and different doses of Atorvastatin. The percentage of subjects experiencing an event is not readable, but the study indicates that Atorvastatin 80 mg resulted in a lower occurrence of a major cardiovascular endpoint compared to a lower dosage. The study also reports a hazard ratio of 0.78 with a confidence interval for the effect of the treatment. Time in years is also presented on the graph.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.